RO5166017
Sign in to saveAlso known as RO 5166017, RO-5166017
RO5166017, or RO-5166017, is a drug developed by Hoffmann-La Roche which acts as a potent and selective agonist for the trace amine-associated receptor 1 (TAAR1), with no significant activity at other targets. It is a partial agonist or near-full agonist depending on the species.
Wikidata facts
- Mass
- 219.137162
Show 4 more facts
- chemical formula
- C₁₂H₁₇N₃O
- isomeric SMILES
- CCN(C[C@H]1COC(=N1)N)C2=CC=CC=C2
- canonical SMILES
- CCN(CC1COC(=N1)N)C2=CC=CC=C2
- Commons category
- RO5166017
Sources (1)
via Wikidata · CC0
~5 min read
Article
8 sectionsContents
- Pharmacology
- Pharmacodynamics
- Actions
- Effects
- Pharmacokinetics
- History
- See also
- References
RO5166017, or RO-5166017, is a drug developed by Hoffmann-La Roche which acts as a potent and selective agonist for the trace amine-associated receptor 1 (TAAR1), with no significant activity at other targets. It is a partial agonist or near-full agonist depending on the species.
The drug is important for the study of the TAAR1 receptor, as while numerous other compounds are known which act as TAAR1 agonists, such as methamphetamine, MDMA, and 3-iodothyronamine, all previously known TAAR1 agonists are either weak and rapidly metabolized (endogenous ligands), or have strong pharmacological activity at other targets (amphetamines, thyronamines), making it very difficult to assess which effects are due to TAAR1 activation. The discovery of RO-5166017 allows purely TAAR1 mediated effects to be studied.